Cost-effectiveness analysis of EGFR mutation testing in patients with non-small cell lung cancer (NSCLC) with gefitinib or carboplatin–paclitaxel
Arrieta, Oscar, Anaya, Pablo, Morales-Oyarvide, Vicente, Ramírez-Tirado, Laura Alejandra, Polanco, Ana C.Volume:
17
Language:
english
Journal:
The European Journal of Health Economics
DOI:
10.1007/s10198-015-0726-5
Date:
September, 2016
File:
PDF, 1010 KB
english, 2016